Comparison of the performance of serological kits for Helicobacter pylori infection with European and Asian study populations T.T.H. Hoang, A.-S. Rehnberg,

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

MicroRNA profiling in duodenal ulcer disease caused by Helicobacter pylori infection in a Western population S. Lario, M.J. Ramírez-Lázaro, A.M. Aransay,

Laboratory diagnosis and biosafety issues of biological warfare agents

Helicobacter pylori infection and gastric carcinoma

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

P.-Y. Lévy Clinical Microbiology and Infection

Helicobacter pylori resistance to antibiotics in 2014 in France detected by phenotypic and genotypic methods A. Ducournau, L. Bénéjat, E. Sifré, E. Bessède,

L. Boyanova Clinical Microbiology and Infection

Helicobacter pylori infection and gastric carcinoma

Gut bacterial microbiota and obesity

Approach to diagnosis of infective endocarditis

Varicella vaccination: a laboured take-off

Herpes zoster in non-hospitalized children

Migrant health—a cause for concern?

M.L. McMorrow, M. Aidoo, S.P. Kachur

Clinical characteristics of Haemophilus influenzae meningitis in Denmark in the post- vaccination era T.I. Pedersen, M. Howitz, C. Østergaard Clinical.

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

J.-P. Van geertruyden Clinical Microbiology and Infection

Hepatitis B and C virus-related carcinogenesis

Laboratory handling of Helicobacter pylori critically influences the results of in-vitro metronidazole resistance determination T.H. Henriksen, F. Lerang,

The use of AP-PCR and flaA-RFLP typing to investigate treatment failure in Helicobacter pylori infection I. Adamsson, C. Edlund, R. Seensalu, L. Engstrand

R. Cantón Clinical Microbiology and Infection

Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus P.-R. Hsueh, L.-M. Huang, P.-J.

Louis Pasteur, from crystals of life to vaccination

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

Assessment of the cag pathogenicity island status of Helicobacter pylori infections with serology and PCR M. Kivi, Y. Tindberg, C. Bengtsson, L. Engstrand,

Clinical Microbiology and Infection

Surveillance of Legionnaires’ disease in Austria

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

Vector control: a cornerstone in the malaria elimination campaign

L. Gatta, C. Ricci, A. Tampieri, D. Vaira

Training for the infectious diseases speciality in Norway

E.C. Böttger Clinical Microbiology and Infection

R. Karakus, K. Caglar, C. Aybay Clinical Microbiology and Infection

Laboratory diagnosis and biosafety issues of biological warfare agents

Antimicrobial susceptibility in Escherichia coli of human and avian origin—a comparison of wild-type distributions M. Sjölund, S. Bengtsson, J. Bonnedahl,

Levofloxacin in the treatment of ventilator-associated pneumonia

G. Pappas Clinical Microbiology and Infection

Acute schistosomiasis, a diagnostic and therapeutic challenge

Metagenomics and probiotics

Effect of antioxidants on the immune response of Helicobacter pylori

Hepatitis B and C virus-related carcinogenesis

Laboratory diagnosis of Clostridium difficile disease

N. Maggi-Solcà, C. Valsangiacomo, J.-C. Piffaretti

A case of pleurisy associated with antibodies to Rickettsia conorii

The practice of travel medicine in Europe

The role of antimalarial treatment in the elimination of malaria

Abstracts cont. Clinical Microbiology and Infection

Pandemic lineages of extraintestinal pathogenic Escherichia coli

Evaluation of eight commercial tests for Mycoplasma pneumoniae antibodies in the absence of acute infection R. Nir-Paz, A. Michael-Gayego, M. Ron, C.

The use of AP-PCR and flaA-RFLP typing to investigate treatment failure in Helicobacter pylori infection I. Adamsson, C. Edlund, R. Seensalu, L. Engstrand

Statin use and clinical outcomes among pneumonia patients

Clinical Microbiology and Infection

Evaluation of the performance of the Helico Blot 2

Real-time comparative monitoring of the A/H1N1 pandemic in France

K. Kaier, N.T. Mutters, U. Frank Clinical Microbiology and Infection

Systematic reviews and meta-analyses of diagnostic test accuracy

The atypical pneumonias: clinical diagnosis and importance

J.J. Keller, M.-C. Tsai, C.-C. Lin, Y.-C. Lin, H.-C. Lin

Abstracts Clinical Microbiology and Infection

Modelling during an emergency: the 2009 H1N1 influenza pandemic

Usefulness of a quantitative real-time PCR assay using serum samples to discriminate between inactive, serologically positive and active human brucellosis

Antibiotic resistance of Helicobacter pylori: a cross-sectional study in consecutive patients, and relation to ethnicity R.J.L.F. Loffeld, C.A.P.M.J.

Are we losing the fight against malaria one more time?

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

Impact of antibiotic restrictions: the patient's perspective

Comparative study of pediculicidal effect of medical plants

CMI readers' survey Clinical Microbiology and Infection

The future of diagnostic bacteriology

Presentation transcript:

Comparison of the performance of serological kits for Helicobacter pylori infection with European and Asian study populations T.T.H. Hoang, A.-S. Rehnberg, T.-U. Wheeldon, C. Bengtsson, D.C. Phung, R. Befrits, M. Sörberg, M. Granström Clinical Microbiology and Infection Volume 12, Issue 11, Pages 1112-1117 (November 2006) DOI: 10.1111/j.1469-0691.2006.01514.x Copyright © 2006 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 1 A–C, Reverse cumulative graphs of antibody concentrations in the ELISA assays. The dotted lines represent cut-off levels in the respective assays. D, Proportion of responders to the diagnostic bands in the Helicoblot 2.1 kit (Vn, Vietnamese; Sw, Swedish; PUD, peptic ulcer disease; GU, gastric ulcer). Clinical Microbiology and Infection 2006 12, 1112-1117DOI: (10.1111/j.1469-0691.2006.01514.x) Copyright © 2006 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 2 Receiver operating characteristic (ROC) curves for (A) Pyloriset EIA-GIII and (B) HM-CAP ELISA values with the Vietnamese study populations, as used for the establishment of an optimal cut-off level. Clinical Microbiology and Infection 2006 12, 1112-1117DOI: (10.1111/j.1469-0691.2006.01514.x) Copyright © 2006 European Society of Clinical Infectious Diseases Terms and Conditions